The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

Fintel reports that on July 23, 2025, BMO Capital downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Underperform. Analyst Price Forecast Suggests 595.73% Upside As of ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

Helen Of Troy Guides Q2 Well Below Estimates; Stock Plummets 20% - Update July 10, 2025 — 07:28 am EDT Written by RTTNews.com for RTTNews -> ...

Stock Market Plummets as Trump Announces Tariffs Start Date Donald Trump is back at it with his haphazard tariff announcements.

Replimune Group (NASDAQ:REPL – Get Free Report) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports ...

Influencer Ashley Stock has welcomed a baby girl five years after her 3-year-old daughter Stevie died from brain cancer.